TD Cowen analyst Marc Frahm has maintained their bullish stance on SANA stock, giving a Buy rating on March 14.
Marc Frahm has given his Buy rating due to a combination of factors that highlight Sana Biotechnology’s promising developments and strategic direction. The company reported a significant cash position, providing a financial runway into 2026, which supports its ongoing and future research initiatives. Sana’s innovative approach in modifying human islet cells for type 1 diabetes has shown encouraging results, with the cells functioning effectively at 12 weeks without immune suppression, indicating a strong potential for this technology.
Additionally, Sana’s pipeline includes promising trials such as SC291 and SC262, targeting autoimmune disorders and B-cell malignancies, with data expected in 2025. The anticipation of filing INDs for SC451 and SG299 by 2026 further underscores the company’s robust research and development strategy. These factors collectively suggest a de-risked profile for Sana’s technologies and a positive outlook for its future growth, justifying the Buy rating.
In another report released on March 14, Jefferies also initiated coverage with a Buy rating on the stock with a $7.00 price target.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SANA in relation to earlier this year.